Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-blind, Randomized, Placebo and Active-controlled Study of Pregabalin for the Treatment of Uremic Pruritus
Brief Summary: Pruritus s a very distressing problem affecting patients with uremia and the prevalence of uremic pruritus (UP) ranges between 22% to 66%. Although some studies suggested pruritus is being decreased recently by use of better dialysis techniques, accumulating studies have shown the still high prevalence of UP. Because of its long duration, frequency and high intensity, UP has been reported to have a negative impact upon the patients' quality of life (QoL). However, the therapies in use, including antihistamines, ultraviolets, opioid antagonists and topical agents, are generally of insufficient efficacy, failing to provide adequate and long-lasting relief. Based on the neuropathic hypothesis and frequent co-occurrence of chronic pruritus and peripheral neuropathy in the patients undergoing hemodialysis, gabapentin, a medication widely used for a spectrum of neuropathic pain syndromes, has recently been suggested to be effective in the treatment of UP.Pregabalin, another gabaergic drug structurally related to gabapentin, have an advantage over gabapentin in terms of its more rapid response to stressful symptoms. Only two very recently small-scaled studies evaluate the effect of pregabalin for UP. However, both these studies were not randomized, placebo-controlled trails.As UP is still one of the most vexing and disabling symptoms in patients with ESRD, we decided to do this multicenter, randomized double-blind placebo-controlled trial (RCT) with a larger sample size and a longer duration.


Options:
A: Arm Label: CR845 0.5mcg/kg; Type: EXPERIMENTAL; Interventions: Drug: CR845 0.5 mcg/kg | Arm Label: CR845 1 mcg/kg; Type: EXPERIMENTAL; Interventions: Drug: CR845 1 mcg/kg | Arm Label: CR845 1.5mcg/kg; Type: EXPERIMENTAL; Interventions: Drug: CR845 1.5mcg/kg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CR845 0.5 mcg/kg; Assigned to Arm(s): CR845 0.5mcg/kg | Intervention Type: DRUG; Name: CR845 1 mcg/kg; Assigned to Arm(s): CR845 1 mcg/kg | Intervention Type: DRUG; Name: CR845 1.5mcg/kg; Assigned to Arm(s): CR845 1.5mcg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: pregabalin 75mg daily for 12 weeks | Arm Label: fexofenadine; Type: ACTIVE_COMPARATOR; Interventions: Drug: fexofenadine 60 mg daily for 12 weeks | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin 75mg daily for 12 weeks; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: fexofenadine 60 mg daily for 12 weeks; Assigned to Arm(s): fexofenadine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: D